Related Experiment Video
Updated: May 31, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
Bone sarcomas and cancer predisposition syndromes.
Camille Tlemsani1, Gaëlle Bougeard2, Marion Gauthier-Villars3
1Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, AP-HP, Université Paris Cité, Paris, France; Institut Cochin, Inserm U1016, CNRS UMR8104, CARPEM, Université Paris Cité, Paris, France.
Identifying genetic predisposition syndromes is crucial for managing bone sarcomas. This review offers guidance on detecting and managing these rare cancers in patients with inherited cancer predisposition syndromes.
Area of Science:
- Oncology
- Genetics
- Medical Research
Background:
- Bone sarcomas are rare malignant neoplasms, often linked to genetic susceptibility syndromes.
- Less than 1% of all malignant neoplasms are bone sarcomas, affecting all age groups.
- Understanding genetic links is vital for early detection and management.
Purpose of the Study:
- To provide recommendations for detecting cancer predisposition syndromes in bone sarcoma patients.
- To guide the management of patients with bone sarcomas and associated genetic syndromes.
- To review tumour presentation, management, and follow-up strategies within the context of inherited predispositions.
Main Methods:
- Multidisciplinary working group including geneticists, oncologists, and radiologists.
- Review of tumour presentation, management strategies, and follow-up for specific bone sarcomas.
- Analysis of genetic syndromes associated with osteosarcomas, chondrosarcomas, and Ewing sarcomas.
Main Results:
- Li-Fraumeni syndrome (TP53 variants) is the most frequent predisposition for osteosarcoma.
- RB1, RECQ, CDKN2A disorders (osteosarcomas) and Ollier/Maffucci diseases (chondrosarcomas) are also recognized.
- Somatic molecular variation identification aids in detecting constitutional germline variants.
Conclusions:
- Early identification of cancer predisposition syndromes improves bone sarcoma patient outcomes.
- Tailored treatment approaches can mitigate toxicities and secondary oncological events.
- Collaboration through screening programs, networks, and molecular tumor boards is essential for optimal care.
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
Cancer Prevention
Some...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

